Research Report Screener Results

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 23)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
6-Feb-10 Standard & Poor's Quantitative Report N/A YM BioSciences 6 $25 View Abstract
6-Feb-10 Reuters Investment Profile N/A YM BioSciences Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
2-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for YMI: the economy's impact on YMI's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
31-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: YM BIOSCIENCES INC 5 $25 View Abstract
26-Jan-10 Zacks Investment Research Inc. N/A YM BIOSCI INC (YMI) Zacks Company Snapshot 1 $10 View Abstract
26-Jan-10 Roth Capital Partners, Inc. Joe Pantginis PhD Nimotuzumab Expansion into U.S. Progresses 4 $10 View Abstract
24-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: YM BIOSCIENCES INC 5 $25 View Abstract
17-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: YM BIOSCIENCES INC 5 $25 View Abstract
11-Jan-10 Zacks Investment Research Inc. N/A YM BIOSCI INC (YMI) Zacks Company Snapshot 1 $10 View Abstract
8-Jan-10 Zacks Investment Research Inc. N/A YM BIOSCI INC (YMI) Zacks Company Snapshot 1 $10 View Abstract
Next 13

Brokerage Reports (Showing 1 to 3 of 3)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
26-Jan-10 Roth Capital Partners, Inc. Joe Pantginis PhD Nimotuzumab Expansion into U.S. Progresses 4 $10 View Abstract
7-Jan-10 Roth Capital Partners, Inc. Research Department Morning Call Summary 15 $50 View Abstract
7-Jan-10 Roth Capital Partners, Inc. Joe Pantginis PhD YMI: Invitation to Nimotuzumab's Coming Out Party in North America 18 $50 View Abstract

Independent Reports (Showing 1 to 10 of 20)

Release
Date Contributor Author Title Pages Price More Info
6-Feb-10 Standard & Poor's Quantitative Report N/A YM BioSciences 6 $25 View Abstract
6-Feb-10 Reuters Investment Profile N/A YM BioSciences Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
2-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for YMI: the economy's impact on YMI's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
31-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: YM BIOSCIENCES INC 5 $25 View Abstract
26-Jan-10 Zacks Investment Research Inc. N/A YM BIOSCI INC (YMI) Zacks Company Snapshot 1 $10 View Abstract
24-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: YM BIOSCIENCES INC 5 $25 View Abstract
17-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: YM BIOSCIENCES INC 5 $25 View Abstract
11-Jan-10 Zacks Investment Research Inc. N/A YM BIOSCI INC (YMI) Zacks Company Snapshot 1 $10 View Abstract
8-Jan-10 Zacks Investment Research Inc. N/A YM BIOSCI INC (YMI) Zacks Company Snapshot 1 $10 View Abstract
7-Jan-10 Zacks Investment Research Inc. N/A YM BIOSCI INC (YMI) Zacks Company Snapshot 1 $10 View Abstract
Next 10

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.